Natriuretic peptides as markers of cardiovascular risk: The story continues

Mayo Clinic Proceedings

Volumn 86, Issue 12, 2011, Pages 1143-1145

  Ventura, Hector O ^a   Silver, Marc A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE MARKER; EDITORIAL; HEART FAILURE; HEMODYNAMICS; HUMAN; MORBIDITY; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; RISK ASSESSMENT;

EID: 83155182720     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0725     Document Type: Editorial

References (22)

1. Jacques J. Hippocrates: Medicine and Culture. DeBevoise MB, Trans. Baltimore, MD: Johns Hopkins University Press, 1999.
2. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab. 2005;16:469-477.
3. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348-353.
4. Lafontan M, Moro C, Sengenes C, Galitzky J, Crampes F, Berlan M. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Arterioscler Thromb Vasc Biol. 2005;25:2032- 2042.
5. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005; 80(8):1029-1036. (Pubitemid 41099389)
6. Maisel AS, Krishnaswamy P, Novak RM, et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167. (Pubitemid 34764819)
7. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci. 2005;108:23-36. (Pubitemid 40052282)
8. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-2397. (Pubitemid 34556391)
9. Olsen MH, Wachtell K, Tuxen C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens. 2004;22(8):1597- 1604.
10. Cannone V, McKie PM, Burnett JC. Can a cardiac peptide predict mortality in human hypertension. Hypertension. 2011;57:670-671.
11. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
12. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation. 2003;108:275-281. (Pubitemid 36899016)
13. Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation. 2005;112:110-116. (Pubitemid 40962576)
14. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial. Circulation. 2003;107:2786-2792. (Pubitemid 36705987)
15. Bibbins-Domingo K, Gupta R, Na B, Wu AHB, Schiller NB, Whooley MA. N- terminal fragment of the prohormone brain-type natriuretic peptide (NT-pro BNP), cardiovascular events, and mortality in patients with stable coronary disease. JAMA. 2007;297:169-176. (Pubitemid 46089733)
16. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and Nterminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201-208. (Pubitemid 44297113)
17. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666-675. (Pubitemid 40239214)
18. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663. (Pubitemid 38364624)
19. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55:2140-2147.
20. McKie PM, Cataliotti A, Sangaralingham SJ, et al. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011;86(12):1154-1160.
21. Januzzi JL. Use of biomarkers to "guide" care in chronic heart failure: what have we learned (so far)? J Card Fail. 2011;17:622-625.
22. Conan Doyle A. The Adventures of Sherlock Holmes. London, England: George Newnes Ltd; 1892:163.